IBD Science for Patients

If you live with ulcerative colitis (UC), you are likely very familiar with the “stool test.” Doctors use a marker called faecal calprotectin to check for inflammation in your gut without having to perform a colonoscopy every time. While accurate, these tests can be inconvenient and sometimes messy. Now, a new study published in July has identified a promising new signal in your blood, called REG3α, that could make tracking your disease much easier.

What the Research Found

This was a medium-sized prospective study involving 128 patients with ulcerative colitis. Researchers collected blood samples on the same day patients had their endoscopies to see if the levels of certain proteins in the blood matched the actual “view” inside the gut.

The star of the study was a protein called REG3α (short for Regenerating islet-derived protein 3 alpha). This protein is made by special “guardian” cells in your gut called Paneth cells.

The key findings were:

• A Clear Signal: The levels of REG3α in the blood were significantly higher in patients whose UC was active compared to those in remission.
• The Power of Two: When researchers combined the REG3α blood signal with the standard CRP (C-reactive protein) test, the accuracy in predicting a flare-up reached nearly 85%.
• Tracking Recovery: In a smaller group of 19 patients who were tracked over time, REG3α levels dropped significantly as they began to feel better and their gut started to heal.

Why This Matters to You as a Patient

For anyone who has struggled to provide a stool sample on demand or waited weeks for results, this research is a breath of fresh air:

1. Less Invasive Monitoring: If validated in larger trials, this could lead to a simple blood test that gives your doctor a detailed “map” of your gut health without needing a stool sample or a frequent colonoscopy.
2. A “Real-Time” Dashboard: Because REG3α is produced directly by cells in the gut lining, it provides a more specific “gut-focused” signal than CRP, which can go up for many different reasons (like a common cold).
3. Faster Treatment Tweaks: Because the levels drop as you heal, doctors might be able to use this test to see if a new medicine is working within weeks, rather than waiting months to see if your symptoms improve.

While this is an exploratory study and needs to be tested in larger groups of patients before it becomes standard care, it marks a step toward personalised, blood-based monitoring for IBD.

Explore the Research

• Original Article: Serum REG3α as a biomarker for clinical and endoscopic activity in ulcerative colitis.
• Comparing Tests: The role of faecal calprotectin in IBD.